Clarifying the role of rasburicase in tumor lysis syndrome
Tumor lysis syndrome (TLS) is a complication of malignancies with high tumor cell proliferation, tumor burden, and chemosensitivity. It manifests with the release of intracellular components and results in hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia. These biochemical abnormalities may lead to serious complications such as renal failure, cardiac dysrhythmias, and death. Rasburicase, a recombinant urate oxidase enzyme, is a new agent indicated in the treatment or prophylaxis of hyperuricemia in pediatric patients with cancer who are at high risk for TLS. We reviewed the evidence for treatment with this agent compared with standard therapy with allopurinol. Rasburicase may be considered for use in patients with hyperuricemia at presentation and in patients at high risk for TLS that would otherwise result in a delay in chemotherapy. However, randomized controlled trials are required to establish the comparative efficacy of rasburicase in the adult population. Preliminary evidence suggests that single-dose or reduced-dose rasburicase may be effective in the prophylaxis and the treatment of hyperuricemia and TLS. However, to our knowledge, there is no evidence comparing clinically relevant outcomes such as acute renal failure or dialysis.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2007 |
|---|---|
| Erschienen: |
2007 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Pharmacotherapy - 27(2007), 1 vom: 04. Jan., Seite 111-21 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sood, Amy R [VerfasserIn] |
|---|
| Themen: |
08GY9K1EUO |
|---|
| Anmerkungen: |
Date Completed 21.03.2007 Date Revised 08.11.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM167408941 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM167408941 | ||
| 003 | DE-627 | ||
| 005 | 20231223112855.0 | ||
| 007 | tu | ||
| 008 | 231223s2007 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n0558.xml |
| 035 | |a (DE-627)NLM167408941 | ||
| 035 | |a (NLM)17192165 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sood, Amy R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clarifying the role of rasburicase in tumor lysis syndrome |
| 264 | 1 | |c 2007 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 21.03.2007 | ||
| 500 | |a Date Revised 08.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Tumor lysis syndrome (TLS) is a complication of malignancies with high tumor cell proliferation, tumor burden, and chemosensitivity. It manifests with the release of intracellular components and results in hyperkalemia, hyperphosphatemia, hypocalcemia, and hyperuricemia. These biochemical abnormalities may lead to serious complications such as renal failure, cardiac dysrhythmias, and death. Rasburicase, a recombinant urate oxidase enzyme, is a new agent indicated in the treatment or prophylaxis of hyperuricemia in pediatric patients with cancer who are at high risk for TLS. We reviewed the evidence for treatment with this agent compared with standard therapy with allopurinol. Rasburicase may be considered for use in patients with hyperuricemia at presentation and in patients at high risk for TLS that would otherwise result in a delay in chemotherapy. However, randomized controlled trials are required to establish the comparative efficacy of rasburicase in the adult population. Preliminary evidence suggests that single-dose or reduced-dose rasburicase may be effective in the prophylaxis and the treatment of hyperuricemia and TLS. However, to our knowledge, there is no evidence comparing clinically relevant outcomes such as acute renal failure or dialysis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a Gout Suppressants |2 NLM | |
| 650 | 7 | |a rasburicase |2 NLM | |
| 650 | 7 | |a 08GY9K1EUO |2 NLM | |
| 650 | 7 | |a Allopurinol |2 NLM | |
| 650 | 7 | |a 63CZ7GJN5I |2 NLM | |
| 650 | 7 | |a Urate Oxidase |2 NLM | |
| 650 | 7 | |a EC 1.7.3.3 |2 NLM | |
| 700 | 1 | |a Burry, Lisa D |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Doret K F |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacotherapy |d 1983 |g 27(2007), 1 vom: 04. Jan., Seite 111-21 |w (DE-627)NLM012960926 |x 1875-9114 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2007 |g number:1 |g day:04 |g month:01 |g pages:111-21 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2007 |e 1 |b 04 |c 01 |h 111-21 | ||